Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 7/20 | 0.72 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29533051 | 1.00 | HSPB1 (0.72) | HSPB1EPAS1MAPTTDP1L3MBTL1 | |
| SCHEMBL16340463 | 0.96 | HSPB1 (0.67) | HSPB1EPAS1MAPTTDP1L3MBTL1 | |
| SCHEMBL29845685 | 0.86 | HSPB1 (0.53) | HSPB1EPAS1MAPTTDP1L3MBTL1 | |
| SCHEMBL20154998 | 0.86 | HSPB1 (0.53) | HSPB1EPAS1MAPTTDP1L3MBTL1 | |
| SCHEMBL29683621 | 0.86 | HSPB1 (0.49) | HSPB1MAPTTDP1L3MBTL1HTT | |
| SCHEMBL16339880 | 0.85 | HSPB1 (0.62) | HSPB1EPAS1MAPTTDP1L3MBTL1 | |
| SCHEMBL21904820 | 0.84 | HSPB1 (0.71) | HSPB1MAPTTDP1L3MBTL1HTT | |
| SCHEMBL31395357 | 0.84 | HSPB1 (0.71) | HSPB1MAPTTDP1L3MBTL1HTT | |
| SCHEMBL20155187 | 0.83 | HSPB1 (0.59) | HSPB1EPAS1MAPTTDP1L3MBTL1 | |
| SCHEMBL21904840 | 0.82 | HSPB1 (0.72) | HSPB1EPAS1MAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107406-A1 | p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF | Design Therapeutics, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107489-A1 | SOLUBLE FORMULATIONS | Design Therapeutics, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20250276978-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2025-09-04 | — | — | US | disclosed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025076236-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025076219-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025076181-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| EP-2858990-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | AbbVie Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| US-20150005340-A1 | CRYSTALLINE BROMODOMAIN INHIBITORS | ABBVIE INC. | 2015-01-01 | — | — | US | disclosed |
| WO-2014210425-A1 | CRYSTALLINE BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014206345-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| WO-2013185284-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | ABBOTT LABORATORIES (US) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013188381-A1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES | ABBVIE INC. (US) | 2013-12-19 | — | — | WO | disclosed |
| US-20130331382-A1 | Pyridinone and Pyridazinone Derivatives | ABBVIE INC. | 2013-12-12 | — | — | US | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276978-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | HSPB1 653/4885EPAS1 1081/4885MAPT 1405/4885 |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | BRD4, BRD1, BRD3 | HSPB1 633/4885EPAS1 2836/4885MAPT 1460/4885 |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | HSPB1 2386/4885EPAS1 2025/4885MAPT 2252/4885 |
| US-20130331382-A1 | Pyridinone and Pyridazinone Derivatives | CYP4F3, CYP4B1, CYP4F11 | HSPB1 4220/4885EPAS1 830/4885MAPT 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.